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Abstract
The synthesis of the novel electronically modified phosphinooxazoline (PHOX) ligand, (R)-5,5-
dimethyl-(p-CF3)3-i-PrPHOX, is described. The utility of this PHOX ligand is explored in both 
enantio- and diastereoselective palladium-catalyzed allylic alkylations. These investigations prove 
(R)-5,5-dimethyl-(p-CF3)3-i-PrPHOX to be an effective and cost-efficient alternative to 
electronically modified PHOX ligands derived from the prohibitively expensive (R)-t-leucine.
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1. Introduction
Phosphinooxazoline (PHOX) ligands, developed by Helmchen,1 Williams,2 and Pfaltz,3 
have proven to be a privileged ligand scaffold in transition metal catalysis.4 PHOX ligands 
have found application in a variety of asymmetric transition metal-catalyzed transformations 
including asymmetric hydrogenation,5 azomethine ylide cycloadditions,6 intermolecular 
Heck couplings,7 and hydrosilylation8 as well as transition metal-catalyzed allylic 
substitution4,9 and protonation10 reactions. Our lab has extensively explored the utility of 
the PHOX ligand scaffold in the palladium-catalyzed enantioselective allylic alkylation of 
carbocyclic11 and heterocyclic12 substrates. These investigations have revealed 
electronically modified PHOX ligands (i.e. (S)-(p-CF3)3-t-BuPHOX ((S)-L1), Figure 1)13 
can profoundly enhance the rate of reaction as well as yield, enantiomeric excess (ee) and/or 
diastereomeric ratio of a product containing an all-carbon quaternary center (e.g. use of (S)-
L1 vs. (S)-L2 to construct lactam 2,12e cyclohexanone 4,13c cyclohexenone 6,13b and 
cyclohexanone diastereomers 9 and 10,14 Schemes 1A–1C and Scheme 2, respectively).
Most commonly, transition metal complexes employing tert-leucinol-derived PHOX ligands 
(e.g. (S)-L1 and (S)-L2˙, Figure 1) enable the formation of the corresponding products with 
the best enantiomeric and diastereomeric ratios. Although (R)-t-BuPHOX has been 
employed in natural product synthesis15 and explored in transition-metal catalyzed allylic 
alkylations,10a,16 these examples are quite rare considering the nearly prohibitive cost of the 
requisite starting material for ligand synthesis, (R)-t-leucine.17 Previously, 5,5-geminally 
disubstituted (R)-valine-derived PHOX ligands (e.g. (R)-L3 and (R)-L4, Figure 2) have 
been constructed as cost-effective alternatives to (R)-t-BuPHOX ((R)-L2).18 We sought to 
extend this precedent to the synthesis of electronically modified congener (R)-5,5-dimethyl-
(p-CF3)3-i-PrPHOX ((R)-(p-CF3)3-i-PrPHOXMe2, (R)-L5, Figure 2) and explore its efficacy 
as a ligand in palladium-catalyzed enantio-and diastereoselective allylic alkylation reactions.
2. Results and discussion
2.1 Synthesis of (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5)
Synthesis of (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) was initiated with acid chloride 1119 and 
the hydrogen chloride salt of (R)-valine derivative 1218 (Scheme 3). Intermolecular coupling 
of acid chloride 11 and amino alcohol 12 in the presence of excess Et3N provides amide 13 
in 79% yield. Intramolecular cyclization of amide 13 under acidic conditions furnishes 
oxazoline 14 in 87% yield. Completion of desired ligand (R)-L5 was accomplished over two 
steps, beginning with the copper-mediated coupling of phosphine oxide 15 with bromide 14 
at elevated temperature.20 This procedure produces phosphine oxide 16 in 63% yield. 
Reduction of phosphine oxide 16 was subsequently accomplished in neat Ph2SiH2 at 140 °C 
over 48 hours, providing the desired ligand (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) in 81% 
yield in the final step of the synthetic sequence.
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2.2 Use of (R)-(p-CF3)3-i-PrPHOXMe2 in Palladium-Catalyzed Asymmetric Transformations
Application of (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) was initially explored in the 
intermolecular palladium-catalyzed enantioselective allylic alkylation of silyl enol ether 17 
with mesylate 18 (Scheme 4). Previously we disclosed the initial development and 
optimization of this transformation using (S)-t-BuPHOX ((S)-L2), which afforded 
chloroallylketone (S)-19 in 82% yield and 92% ee (entry 1).12d Substitution of (S)-L2 with 
the electronically modified (S)-(p-CF3)3-t-BuPHOX ((S)-L1) provided the product ((S)-19) 
in a slightly diminished 91% ee (entry 2). Switching the ligand to (S)-5,5-diphenyl-i-
PrPHOX ((S)-L3) furnished chloroallylketone (S)-19 in 90% ee (entry 3). Moving into the 
opposite enantiomeric series, the use of (R)-5,5-dimethyl-i-PrPHOX ((R)-L4) provided 
chloroallylketone (R)-19 in a somewhat diminished 89% ee (entry 4) compared to the 
originally optimized reaction conditions (entry 1). Alternatively, we were pleased to find 
that (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) afforded chloroallylketone (R)-19 in the same 
91% ee (entry 5) in the opposite enantiomeric series compared to the use of (S)-(p-CF3)3-t-
BuPHOX (entry 2). It is noteworthy that the required reaction time and isolated yield of 
chloroallylketone 19 were independent of the ligand employed. Thus, (R)-(p-CF3)3-i-
PrPHOXMe2 ((R)-L5) can allow access to the enantiomeric series of products to those 
afforded in reactions employing (S)-L1 without any loss in product ee in a cost-effective 
manner, being derived from (R)-valine, which is less than 2% of the cost of (R)-t-leucine.
The utility of (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) was further demonstrated in the 
intermolecular palladium-catalyzed diastereoselective decarboxylative allylic alkylation of 
β-ketoester 20 with allyl electrophile 21 (Scheme 5).16a While the system displays an 
inherent selectivity for the formation of diastereomer 22 in a 2:1 ratio with diastereomer 23 
when achiral PHOX ligand L6 was employed (entry 1),21 the use of (S)-t-BuPHOX ((S)-L2) 
can override this substrate bias, providing diastereomer 23 as the major product (entry 2). 
Comparatively, the use of (R)-t-BuPHOX ((R)-L2) reinforces the inherent selectivity, 
providing diastereomer 22 in a 12:1 ratio with minor diastereomer 23 in a combined 73% 
yield (entry 3). Pleasingly, the employment of (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) further 
improved this transformation, furnishing an 18:1 mixture of products in favor of 
diastereomer 22 in an improved 85% combined yield (entry 4). These studies revealed that 
(R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) was the optimal ligand for the highly 
diastereoselective formation of allylic alkylation product 22. Additionally, other research 
groups have found (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5) to be a uniquely effective ligand for 
the palladium-catalyzed diastereoselective allylic alkylation of other carbocyclic 
substrates.22
3. Conclusion
Herein, we have disclosed the synthesis of a new, electronically modified 
phosphinooxazoline (PHOX) ligand, (R)-5,5-dimethyl-(p-CF3)3-i-PrPHOX ((R)-(p-CF3)3-i-
PrPHOXMe2, (R)-L5). Derived from (R)-valine, this cost-effective alternative to (R)-(p-
CF3)3-t-BuPHOX ((R)-L1) has proved effective in both palladium-catalyzed enantio- and 
diastereoselective allylic alkylations, furnishing the alkylation products in comparable ee 
and improved diastereomeric ratio. Efforts to further explore the utility of the readily 
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available (R)-(p-CF3)3-i-PrPHOXMe2 ligand in palladium-catalyzed stereoselective 
transformations are currently underway.
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Figure 1. 
Electronically Modified and Unmodified (S)-t-BuPHOX Ligands
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Figure 2. 
5,5-Geminally Disubstituted (R)-Valine-Derived PHOX ligands
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Scheme 1. 
Comparison of Electronically Modified (S)-(p-CF3)3-t-BuPHOX ((S)-L1) and Unmodified 
(S)-t-BuPHOX ((S)-L2) in Intramolecular Palladium-Catalyzed Enantioselective Allylic 
Alkylation
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Scheme 2. 
Comparison of Electronically Modified (S)-(p-CF3)3-t-BuPHOX ((S)-L1) and Unmodified 
(S)-t-BuPHOX ((S)-L2) in Diastereoselective Decarboxylative Alkylation Cascade
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Scheme 3. 
Synthesis of (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-L5)
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Scheme 4. 
Ligand Comparison in Enantioselective Palladium-Catalyzed Intermolecular Allylic 
Alkylation.
Craig and Stoltz Page 11
Tetrahedron Lett. Author manuscript; available in PMC 2016 August 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Scheme 5. 
Diastereoselective Decarboxylative Allylic Alkylation Employing (R)-(p-CF3)3-i-
PrPHOXMe2 ((R)-L5).
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